Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
8.3
5.5
Journals
Biomolecules
Special Issues
Recent Trends in Kidney and Cardiovascular Diseases
share announcement

Recent Trends in Kidney and Cardiovascular Diseases

A special issue of Biomolecules (ISSN 2218-273X). This special issue belongs to the section "Molecular Medicine".

Deadline for manuscript submissions: 30 September 2024 | Viewed by 1067

Special Issue Editor

Dr. Michele Provenzano

E-Mail Website
Guest Editor
Department of Medical and Surgical Sciences, University Magna Graecia of Catanzaro, 88100 Catanzaro, Italy
Interests: epidemiology of Chronic Kidney Disease (CKD): role of prognostic and predictive biomarkers on renal and cardiovascular endpoints; randomized clinical trial design; personalized medicine in nephrology
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

Cardiovascular (CV) diseases play a primary role in the management of patients with chronic kidney disease (CKD). Despite a reduction in the mortality from CV causes in the past decades, particularly due to the increased use of statins and the improved lifestyle, the residual CV risk is striking. As estimated GFR goes down below 60 mL/min, the risk for fatal and non-fatal CV events rapidly increases. More specifically, it is almost duplicated up to 45 mL/min of eGFR and triplicated for eGFR values of 14 to 44 mL/min, as compared to that of patients without CKD. In patients with kidney failure, the last and most advanced stage of CKD, requiring dialysis, CV risk is up to 500-fold higher than that of patients of a similar age but without CKD. Owing to the data, further research efforts are needed to improve the prognosis and treatment of CV disease (including coronary heart disease, heart failure, peripheral vascular disease, cerebral vascular disease). Further studies may encompass research from animal models to patient data and our aim with the following Special Issue is to collect articles, reviews, communications and editorials. Basic research, in vitro and in vivo investigations and pre-clinical studies are welcome.

Dr. Michele Provenzano
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Biomolecules is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • chronic kidney disease
  • cardiovascular risk
  • albuminuria
  • epidemiology
  • estimated glomerular filtration rate

Published Papers (1 paper)

Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

13 pages, 1742 KiB  
Article
Circulating miRNA 122-5p Expression Predicts Mortality and Cardiovascular Events in Chronic Hemodialysis Patients: A Multicentric, Pilot, Prospective Study
by Anila Duni, Marta Greco, Pierangela Presta, Roberta Arena, Ethymios Pappas, Lampros Lakkas, Katerina K. Naka, Antonio Brunetti, Daniela Patrizia Foti, Michele Andreucci, Giuseppe Coppolino, Evangelia Dounousi and Davide Bolignano
Biomolecules 2023, 13(11), 1663; https://doi.org/10.3390/biom13111663 - 17 Nov 2023
Viewed by 796
Abstract
Background: Despite patients undergoing chronic hemodialysis (HD) being notoriously prone to adverse cardiovascular (CV) events, risk prediction in this population remains challenging. miRNA 122-5p, a short, non-coding RNA predominantly involved in lipid and carbohydrate metabolism, has recently been related to the onset and [...] Read more.
Background: Despite patients undergoing chronic hemodialysis (HD) being notoriously prone to adverse cardiovascular (CV) events, risk prediction in this population remains challenging. miRNA 122-5p, a short, non-coding RNA predominantly involved in lipid and carbohydrate metabolism, has recently been related to the onset and progression of CV disease. Methods: We run a pilot, multicenter, longitudinal, observational study to evaluate the clinical significance and prognostic usefulness of circulating miRNA 122-5p in a multicentric cohort of 74 individuals on maintenance HD. Results: Patients displayed lower circulating miRNA 122-5p as compared to healthy controls (p = 0.004). At correlation analyses, ALT (β = 0.333; p = 0.02), E/e’ (β = 0.265; p = 0.02) and CRP (β = −0.219; p = 0.041) were independent predictors of miRNA 122-5p levels. During a median follow-up of 22 months (range of 1–24), 30 subjects (40.5%) experienced a composite endpoint of all-cause mortality and fatal/non-fatal CV events. Baseline circulating miRNA 122-5p was higher in these subjects (p = 0.01) and it predicted a significantly higher risk of endpoint occurrence (Kaplan–Meier crude HR 3.192; 95% CI 1.529–6.663; p = 0.002; Cox regression adjusted HR 1.115; 95% CI 1.009–1.232; p = 0.03). Conclusions: Altered miRNA 122-5p levels in HD patients may reflect hepatic and CV damage and may impart important prognostic information for improving CV risk prediction in this particular setting. Full article
(This article belongs to the Special Issue Recent Trends in Kidney and Cardiovascular Diseases)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-1
Back to TopTop